Get the Stockscreener App
116.43
2.26%
2.57
After Hours:
116.45
0.02
+0.02%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Abbott Laboratories stock is traded at $116.43, with a volume of 4.96M.
It is up +2.26% in the last 24 hours and up +7.10% over the past month.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
See More
Previous Close:
$113.86
Open:
$114.46
24h Volume:
4.96M
Relative Volume:
0.85
Market Cap:
$202.52B
Revenue:
$40.73B
Net Income/Loss:
$5.56B
P/E Ratio:
39.60
EPS:
2.94
Net Cash Flow:
$5.65B
1W Performance:
+2.79%
1M Performance:
+7.10%
6M Performance:
-3.75%
1Y Performance:
+15.59%
1-Day Range:
$114.32
$116.73
1-Week Range:
$112.52
$116.73
52-Week Range:
$89.67
$121.64
Abbott Laboratories Stock (ABT) Company Profile
Name
Abbott Laboratories
Sector
Industry
Phone
(224) 667-6100
Address
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-30-24 | Initiated | Goldman | Buy |
| Jul-21-23 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| May-30-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-20-23 | Reiterated | Barclays | Overweight |
| Apr-20-23 | Reiterated | Bernstein | Outperform |
| Apr-20-23 | Reiterated | JP Morgan | Overweight |
| Apr-20-23 | Reiterated | Raymond James | Outperform |
| Apr-20-23 | Reiterated | UBS | Buy |
| Apr-20-23 | Reiterated | Wolfe Research | Underperform |
| Mar-29-23 | Initiated | UBS | Buy |
| Oct-26-22 | Initiated | Mizuho | Neutral |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-06-22 | Initiated | Wolfe Research | Underperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Jan-27-22 | Reiterated | Credit Suisse | Outperform |
| Jan-27-22 | Reiterated | Morgan Stanley | Overweight |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | UBS | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-27-21 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-14-21 | Initiated | Redburn | Neutral |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Jan-28-21 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-11-20 | Initiated | Wolfe Research | Outperform |
| Jun-01-20 | Downgrade | Goldman | Neutral → Sell |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| Feb-07-19 | Reiterated | BofA/Merrill | Buy |
| Jan-02-19 | Downgrade | Citigroup | Neutral → Sell |
| Nov-30-18 | Upgrade | Goldman | Neutral → Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Jan-30-18 | Reiterated | Citigroup | Neutral |
| Jan-25-18 | Reiterated | Stifel | Buy |
| Jan-25-18 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-03-18 | Initiated | Evercore ISI | Outperform |
| Jan-02-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-19-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-19-17 | Reiterated | Stifel | Buy |
View All
Abbott Laboratories Stock (ABT) Latest News
Abbott Laboratories stock outperforms competitors on strong trading day - MarketWatch
3 Things You Need to Know if You Buy AbbVie Stock Today - The Motley Fool
Report: Abbott begins leadless pacemaker launch in UK - Mass Device
$12.5 Bn Influenza Vaccine Market to 2032 by Vaccine Type, Technology, Age Group, Route of Administration, and Region - GlobeNewswire Inc.
Hematology Market Huge Growth in Future Scope 2024-2031 | Abbott - openPR
Nerve Repair and Regeneration Market 2024 Growing Opportunity and Competitive landscape – Abbott Laboratories, Axogen Corporation, Baxter, Boston Scientific Corporation – Cauverynews - Cauverynews
mHealth and Home Monitoring Market 2024: 76.7 Million Patients Worldwide were Remotely Monitored in 2023, Reflecting Growing Market Acceptance - GlobeNewswire Inc.
Peripheral Vascular Devices Market 2024 Leading Competitors – Angioscore Inc., Abbott Laboratories, Edward Lifesciences Corporation, Jude Medical – Cauverynews - Cauverynews
We Bought The Most Profitable Healthcare Stock Ever - Nanalyze
Abbott Hit With False Ad Suit Over Toddler Nutrition Drink - Law360
Abbott, Baxter and Medtronic among firms hit with recalls - BioWorld Online
Abbott FreeStyle Libre 3 CGM Recall Designated Class I - MD+DI
September 2025 Options Now Available For Abbott Laboratories (ABT) - Nasdaq
FDA hits Abbott FreeStyle Libre 3 recall with Class I tag - Medical Device Network
Abbott's Lingo CGM System Gains U.S. Availability: Stock to Gain? - Zacks Investment Research
Abbott brings 'world's first' dual-chamber leadless pacemaker to the UK - Med-Tech Innovation
Abbott will test whether its 'pacemaker' for the brain can treat depression - Crain's Chicago Business
NEC Infant Formula Update - LawyersandSettlements.com
In Vitro Diagnostics (IVD) Quality Controls Global Markets, 2029 with Abbott, bioMerieux, F. Hoffmann-La Roche Ltd., Siemens Healthineers, and Thermo Fisher Scientific Dominating - GlobeNewswire Inc.
Bombay High Court restrains Abbott's ad, grants temporary relief to HUL: Report - Storyboard18
Abbott's Blood Sugar Sensor for People Without Diabetes Now Available for Sale - CNET
Abbott expands pump partnerships, launches Lingo CGM - BioWorld Online
Abbott Laboratories stock outperforms competitors despite losses on the day - MarketWatch
How Abbott Labs Is Leaning Into Obesity Treatment, And Taking On Dexcom - Investor's Business Daily
HC relief to Hindustan Unilever in row over Abbott Laboratories health drink ad - The Morning Context
Abbott Laboratories Recalls Some Sensors For Its Popular FreeStyle Libre 3 Glucose Monitoring System - Yahoo Finance
Is It Worth Investing in Abbott Based on Wall Street's Bullish Views? - Benzinga
Bombay HC grants temporary relief to HUL in case against Abbott Ads - The Economic Times
Safety update: Sensor issue with Abbott CGMs ruled a Class I recall - Cardiovascular Business
Abbott launches over-the-counter glucose monitor, Lingo - Seeking Alpha
Abbott partners with maker of ‘bionic pancreas’ - MedTech Dive
Abbott follows rival Dexcom with OTC glucose monitor launch in US By Reuters - Investing.com
Abbott follows rival Dexcom with OTC glucose monitor launch in US - Yahoo! Voices
Abbott follows rival Dexcom with OTC glucose monitor launch in US - Reuters
Abbott Launches OTC Continuous Glucose Monitor - MD+DI
Abbott just launched a $49 continuous glucose monitor — for people without diabetes - Quartz
Abbott launches Lingo over-the-counter CGM biosensor in the U.S. - Mass Device
Abbott launches over-the-counter continuous glucose monitor in the US - Blue Water Healthy Living
Abbott launches over-the-counter continuous glucose monitor in the US - The Denver Gazette
Abbott Follows Rival Dexcom With OTC Glucose Monitor Launch in US - U.S. News & World Report
Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know - Yahoo Finance
Abbott launches its first over-the-counter continuous glucose monitor in the U.S. - CNBC
Abbott's Lingo™ Continuous Glucose Monitor for Health and Wellness Now Available in the U.S. - PR Newswire
Rx Medical Food Market Growth in Future Scope 2024-2031 | Abbott - openPR
Abbott Laboratories VP sells shares worth over $3,100 - Investing.com
Abbott Laboratories stock underperforms Wednesday when compared to competitors - MarketWatch
Abbott & Beta Bionics Form Collaboration - MD+DI
Abbott’s Mitraclip third trial: Triumph, TEERs and nuanced results - BioWorld Online
Bioelectric Medicine Market Dazzling Worldwide | Major Giants Medtronic, Abbott, NeuroPace - Daily News Mirror
Abbott to Begin Clinical Trial Evaluating Deep Brain Stimulation for Depression - MarketWatch
Abbott initiates study of deep-brain stimulation for treatment-resistant depression - Mass Device
Abbott Laboratories Stock (ABT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Abbott Laboratories Stock (ABT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| MCCOY JOHN A. JR. | VICE PRESIDENT |
Sep 04 '24 |
Sale |
114.83 |
27 |
3,100 |
18,681 |
1.08%
1.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):